Peyronie Disease Clinical Trial
Official title:
Does Size Matter: A Single Case Experimental Design of Limiting the Depth of Penetration During Intercourse
Verified date | August 2019 |
Source | King's College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Our hypothesis is that reducing the length of the penis does not lead to loss of sexual satisfaction or emotional closeness in the female partner. This will be investigated by a single case experimental design in 12 couples.
Status | Completed |
Enrollment | 12 |
Est. completion date | August 1, 2019 |
Est. primary completion date | June 1, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Heterosexual couples in a stable relationship (defined as 6 months or more) 2. Having regular intercourse (defined as on average twice a week). Exclusion Criteria: 1. Any current sexual dysfunction in either partner 2. Any current emotional disorder in either partner 3. Men with a micro-penis |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Centre for Anxiety Disorders and Trauma | London |
Lead Sponsor | Collaborator |
---|---|
King's College London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Sexual Pleasure on a Visual Analogue Scale | Overall Sexual Pleasure on a Visual Analogue Scale between 0-100 | Change between Control phase (A) and phase B, C, or D through study completion, on average 8 weeks | |
Secondary | Sexual Pleasure from Intercourse on a Visual Analogue Scale | Sexual pleasure from intercourse alone on a Visual Analogue Scale between 0-100 | Change between Control phase (A) and phase B, C, or D through study completion, on average 8 weeks | |
Secondary | Emotional Connection on a Visual Analogue Scale | Emotional Connection on a Visual Analogue Scale between 0-100 | Change between Control phase (A) and phase B, C, or D through study completion, on average 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03774264 -
Treatment Response to Xiaflex for Men With Peyronie's Disease
|
||
Recruiting |
NCT05777031 -
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
|
Phase 4 | |
Active, not recruiting |
NCT05871177 -
Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)
|
N/A | |
Recruiting |
NCT05768867 -
French Translation and Validation of the PEYronie's Disease QUESTionnaire
|
||
Recruiting |
NCT04512287 -
PRP for Treatment of Peyronie's Disease
|
Phase 2 | |
Withdrawn |
NCT05646602 -
Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction
|
N/A | |
Recruiting |
NCT03530540 -
Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease.
|
N/A | |
Recruiting |
NCT06303661 -
Non-ablative Radiofrequency and Low Intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease
|
N/A | |
Recruiting |
NCT06065436 -
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
|
N/A | |
Recruiting |
NCT05316714 -
Novel Nanofat Regenerative Surgical Technique for Peyronies' Disease Treatment
|
N/A | |
Completed |
NCT04370652 -
Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum
|
||
Active, not recruiting |
NCT05480683 -
Pelvic CT With Agatston Calcium Score for Peyronie Disease
|
N/A | |
Recruiting |
NCT04821115 -
Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease
|
N/A |